Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: February 15, 2007
Last updated: April 2, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2010
  Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)